{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:56Z","timestamp":1791353756116,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.maturitas.2016.12.003","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T01:34:44Z","timestamp":1481765684000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Abaloparatide: Recombinant human PTHrP (1\u201334) anabolic therapy for osteoporosis"],"prefix":"10.1016","volume":"97","author":[{"given":"Chee Kian","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2016.12.003_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3803\/EnM.2015.30.4.429","article-title":"Emerging therapies for osteoporosis","volume":"30","author":"McClung","year":"2015","journal-title":"Endocrinol Metab."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0010","unstructured":"Bone health and osteoporosis: A report of the Surgeon General. In: United States Department of Health and Human Services PHS, ed. Office of the Surgeon General, 2004."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.beem.2014.08.002","article-title":"Future directions for new medical entities in osteoporosis","volume":"28","author":"Ferrari","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0020","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0030","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1346.002","article-title":"PTHrP and skeletal development","volume":"1068","author":"Kronenberg","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0045","doi-asserted-by":"crossref","unstructured":"F. Cosman, Abaloparatide a new anabolic therapy on the horizon. Bonekey Reports 4 Article number: 661 2015.","DOI":"10.1038\/bonekey.2015.28"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Different effects of PTH 1\u201334, PTH 1\u201384, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open labeled observational study using HR-pQCT","volume":"28","author":"Hansen","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jbmr.2315","article-title":"Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study","volume":"30","author":"Tsai","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","article-title":"Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate","volume":"59","author":"Ma","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0070","first-page":"1","article-title":"Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"31","author":"Cosman","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0075","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0080","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/jbmr.2283","article-title":"Subgroup variations in bone mineral density response to zoledronic acid after hip fracture","volume":"29","author":"Magaziner","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0085","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0100","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","author":"Moreira","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.1658941","article-title":"A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide","volume":"254","author":"Juppner","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration","volume":"110","author":"Tam","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.maturitas.2016.12.003_bib0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0022-3565(24)38276-X","article-title":"Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: evaluation of receptor states and modulation by guanine nucleotide","volume":"289","author":"Hoare","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0130","doi-asserted-by":"crossref","first-page":"28382","DOI":"10.1074\/jbc.M109.022905","article-title":"Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides","volume":"284","author":"Pioszak","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.maturitas.2016.12.003_bib0135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2016.12.003_bib0140","first-page":"S70","article-title":"Long term effect of BA058, a novel human PTHrP analog, restores bone mass in the aged osteopenic ovariectomized cynomolgus monkey","volume":"28","author":"Doyle","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2016.12.003_bib0145","first-page":"S504","article-title":"BA058, a novel human PTHrP analog: reverses ovariectomy-induced bone loss and strength at the lumbar spine in aged cynomolgus monkeys","volume":"28","author":"Doyle","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 1","key":"10.1016\/j.maturitas.2016.12.003_bib0150","first-page":"S18","article-title":"The long term effects of abaloparatide (BA058) on micro-CT and histomorphometry in osteopenic cynomolgus monkeys","volume":"28","author":"Varela","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.maturitas.2016.12.003_bib0155","article-title":"BA058, a novel human PTHrP analog, restores bone density and increases bone strength at the spine and femur in osteopenic rats","volume":"34","author":"Hattersley","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.maturitas.2016.12.003_bib0160","first-page":"S468","article-title":"The long term effects of abaloparatide (BA058) on bone histomorphometry in osteopenic rats","volume":"29","author":"Chouinard","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 1","key":"10.1016\/j.maturitas.2016.12.003_bib0165","first-page":"S373","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to abaloparatide (BA058) or PTH (1\u201334)","volume":"29","author":"Jolette","year":"2014","journal-title":"J. Bone Miner. Res."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512216302729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512216302729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:07:32Z","timestamp":1759914452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512216302729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":33,"alternative-id":["S0378512216302729"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2016.12.003","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abaloparatide: Recombinant human PTHrP (1\u201334) anabolic therapy for osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}